Regulatory News:
UZEDY U.S. net sales reached $85M in Q3 2026, up 96% year-on-year, according to third-quarter results reported today by Medincell's (Paris:MEDCL) partner Teva Pharmaceuticals (NYSE and TASE: TEVA). Teva raised its 2026 UZEDY revenue outlook to $290-$310M, from $270-$290M previously.
UZEDY generated $225M in U.S. net sales over the first nine months of 2026, exceeding the $191M reported for full-year 2025.
UZEDY commercial performance in 2026
Q1 2026 | Q2 2026 | Q3 2026 | |
UZEDY U.S. net sales | $63M | $77M | $85M |
Year-on-year growth | +62% | +43% | +96% |
2026 revenue outlook | $250-280M | $270-290M | $290-310M |
Sales figures and revenue outlook based on disclosures by Teva Pharmaceuticals.
Medincell receives mid- to high-single-digit royalties on UZEDY net sales and is eligible for up to $105M in commercial milestone payments, subject to the achievement of annual sales thresholds.
UZEDY continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. Prescriptions, normalized into months of therapy, increased 62% year-on-year, supported by improved hospital access and continued expansion of the prescriber base, with more than 800 new prescribers added per month.1
UZEDY is a subcutaneous risperidone long-acting injectable (LAI) approved in the U.S. for the treatment of schizophrenia (one- and two-month dosing) and Bipolar I Disorder (one-month dosing).
UZEDY is the first commercial product using Medincell's BEPO technology and is marketed in the United States by Teva. Following its recent FDA approval, the U.S. launch of WELTRUZA, a once-monthly subcutaneous olanzapine LAI based on the same technology platform, is underway. Both products use Medincell's technology under a worldwide licensing agreement with Teva, with the same economic terms.
About Medincell
Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.
These treatments combine active pharmaceutical ingredients with our proprietary BEPO BEPO Star technologies, which enable controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable depot.
Risperidone LAI was the first treatment based on BEPO technology to receive FDA approval, initially for schizophrenia in April 2023 (one- and two-month dosing), and subsequently for Bipolar I Disorder in October 2025 (one-month dosing). It is marketed in the United States by Teva under the brand name UZEDY
Olanzapine LAI as a once-monthly treatment for schizophrenia in adults received FDA approval in October 2026 with launch in the United States by Teva under the brand name WELTRUZA planned in Q4 2026. A European Marketing Authorization Application (MAA) for Olanzapine LAI was also accepted by EMA in May 2026.
Medincell's investigational pipeline includes numerous innovative therapeutic candidates in various stages of development, from formulation to Phase 3 clinical trials. We collaborate with leading pharmaceutical companies and foundations to advance global health through new treatment options.
Headquartered in Montpellier, France, Medincell employs over 150 people representing more than 27 nationalities.
medincell.com
UZEDY and WELTRUZA are trademarks of Teva Pharmaceuticals. Medincell's BEPO technology is licensed to Teva as SteadyTeq, a trademark of Teva Pharmaceuticals.
This press release contains forward-looking statements, including statements regarding Company's expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) its ability to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities.
These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", "expect", "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "potential", "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's universal registration document, filed with the AMF on July 29, 2025, under number D. 25-0580 (the "Universal Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 30 et seq. 26 of the Registration Document.
Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements.
This press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions.
1 Source: Teva Q3 2026 results presentation. IQVIA NPA 2Q26 vs 2Q25 (TRx normalized into patient months of therapy equivalent volume based on dosing regimen); "fastest growing LAI" amongst atypical LAI's (excluding Erzofri) MAT vs PYMAT
View source version on businesswire.com: https://www.businesswire.com/news/home/20261103086889/en/
Contacts:
David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com +33 (0)6 83 25 21 86
Grace Kim
Chief Strategy Officer, U.S. Finance
grace.kim@medincell.com +1 (646) 991-4023
Nicolas Mérigeau Gaëlle Fromaigeat
Media Relations
Medincell@newcap.eu +33 (0)1 44 71 94 94
Louis-Victor Delouvrier Alban Dufumier
Investor Relations France
Medincell@newcap.eu +33 (0)1 44 71 94 94
